Dossier assessment
Crovalimab (paroxysmal nocturnal haemoglobinuria) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Crovalimab (paroxysmal nocturnal haemoglobinuria) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Crovalimab (paroxysmal nocturnal haemoglobinuria) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult and paediatric patients 12 years of age or older with a weight of ≥ 40 kg with paroxysmal nocturnal haemoglobinuria
- Patients with high disease activity, characterized by clinical symptoms of haemolysis: added benefit not proven
- Adult patients who have been treated with a C5 inhibitor for ≥ 6 months and are clinically stable: hint of lesser benefit
- Paediatric patients 12 years of age or older who have been treated with a C5 inhibitor for ≥ 6 months and are clinically stable: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2025-03-06 A G-BA decision was published.
Project details
- Project no.
- A24-94
- Commission
- Commission awarded on 13.09.2024 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Haematology
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A24-94_en
Connected Projects
-
Addendum
Crovalimab (paroxysmal nocturnal haemoglobinuria) – Addendum to Project A24-94
Status: Commission completed